$2.78
4.14% today
NYSE, Dec 30, 10:06 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Target price 2024 - Analyst rating & recommendation

Prime Medicine Classifications & Recommendation:

Buy
85%
Hold
15%

Prime Medicine Price Target

Target Price $13.09
Price $2.78
Potential
Number of Estimates 11
11 Analysts have issued a price target Prime Medicine 2025 . The average Prime Medicine target price is $13.09. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend Prime Medicine to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Prime Medicine stock has an average upside potential 2025 of . Most analysts recommend the Prime Medicine stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 9.07

13 Analysts have issued a sales forecast Prime Medicine 2024 . The average Prime Medicine sales estimate is

$9.1m
Unlock
. This is
1,033.56% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$56.0m 6,900.00%
Unlock
, the lowest is
$591k 26.13%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$14.2m 56.19%
Unlock
2026
$31.3m 121.19%
Unlock
2027
$6.5m 79.19%
Unlock
2028
$16.2m 149.08%
Unlock

4 Analysts have issued an Prime Medicine EBITDA forecast 2024. The average Prime Medicine EBITDA estimate is

$-208m
Unlock
. This is
0.35% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-194m 6.39%
Unlock
, the lowest is
$-218m 5.25%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-187m 78.55%
2024
$-208m 11.37%
Unlock
2025
$-186m 10.41%
Unlock
2026
$-221m 18.42%
Unlock

EBITDA Margin

2025
-1,314.72% 42.64%
Unlock
2026
-703.87% 46.46%
Unlock

6 Prime Medicine Analysts have issued a net profit forecast 2024. The average Prime Medicine net profit estimate is

$-221m
Unlock
. This is
16.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-160m 39.30%
Unlock
, the lowest is
$-251m 4.97%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-286m 49.32%
2024
$-221m 22.63%
Unlock
2025
$-189m 14.62%
Unlock
2026
$-158m 16.43%
Unlock
2027
$-175m 10.86%
Unlock
2028
$-175m 0.15%
Unlock

Net Margin

2025
-1,333.43% 45.34%
Unlock
2026
-503.76% 62.22%
Unlock
2027
-2,683.55% 432.70%
Unlock
2028
-1,079.00% 59.79%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.18 -1.69
49.32% 22.48%
P/E negative
EV/Sales 27.14

6 Analysts have issued a Prime Medicine forecast for earnings per share. The average Prime Medicine <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.69
Unlock
. This is
15.92% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.22 39.30%
Unlock
, the lowest is
$-1.91 4.98%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.18 49.32%
2024
$-1.69 22.48%
Unlock
2025
$-1.44 14.79%
Unlock
2026
$-1.20 16.67%
Unlock
2027
$-1.33 10.83%
Unlock
2028
$-1.34 0.75%
Unlock

P/E ratio

Current -1.44 70.61%
2024
-1.72 19.44%
Unlock
2025
-2.01 16.86%
Unlock
2026
-2.41 19.90%
Unlock
2027
-2.17 9.96%
Unlock
2028
-2.17 0.00%
Unlock

Based on analysts' sales estimates for 2024, the Prime Medicine stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

27.14
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
41.94
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 307.61
2024
27.14 91.18%
Unlock
2025
17.37 35.98%
Unlock
2026
7.85 54.79%
Unlock
2027
37.74 380.52%
Unlock
2028
15.15 59.85%
Unlock

P/S ratio

Current
2024
41.94 91.18%
Unlock
2025
26.85 35.98%
Unlock
2026
12.14 54.79%
Unlock
2027
58.34 380.52%
Unlock
2028
23.42 59.85%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today